HSF1 and cancer: Studies have shown that the cancer immunogenic lncRNA LIMIT, by targeting the LIMIT-GBP-HSF1 signaling axis, may restore MHC-I expression and function by cancer immunotherapy, which may also strengthen the T-cell-mediated immune response against cancers.